Business & Finance |
Emyria

Emyria and MMA launch MDMA-assisted therapy program for PTSD

Highlights: 

  • Emyria and Mind Medicine Australia announce their first psychedelic-assisted therapy care program (EMDMA-001) for sufferers of treatment resistant post traumatic stress disorder (PTSD)

  • EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS) 

  • Pending successful ethics review and the finalisation of all logistics,, EMDMA-001 will commence with a Phase II, open-label clinical trial of MDMA-assisted psychotherapy at Emyria’s fit-for-purpose clinic in Melbourne before expanding to other sites 

  • EMDMA-001 will utilise specially-trained psychotherapists graduating from Mind Medicine Australia’s first Certificate in Psychedelic-Assisted Therapy (CPAT) training program end of this month 

  • EMDMA-001 will leverage Emyria’s established clinical infrastructure and data capture technology to provide safe patient access while also generating high quality, Real-World Evidence to inform future development  

  • It is expected that this first program will be an important first step towards delivering safe, accredited, cost-effective, scalable and evidence-based, psychedelic-assisted therapy services across Australia


Emyria Limited (ASX: EMD) (Emyria or the Company), an innovative drug development and clinical services company, is pleased to announce the launch of EMDMA-001, a psychedelic-assisted therapy program targeting Posttraumatic Stress Disorder (PTSD) developed with partner Mind Medicine Australia. 


Emyria’s Managing Director, Dr. Michael Winlo says: 

“There is growing international interest in the promise of psychedelic-assisted therapies for treating our most challenging mental health conditions. However, the care model and the drug intervention are intrinsically linked. This means any treatment will require a properly prepared and equipped clinical service - including specially trained clinicians and therapists. We also require more robust clinical evidence to guide future innovation and development in this space. 


At Emyria, our strength is in providing safe access to unregistered treatments while also generating clinical evidence. To date, we have cared for over 4,000 patients with major unmet needs (including more than 80 patients suffering with treatment resistant PTSD) and collected high-quality Real-World Evidence. 


Emyria’s clinical advisory, site network and data infrastructure is uniquely positioned to support safe and scalable psychedelic-assisted therapy, much like we have demonstrated and accomplished with cannabinoid medicines. 


Our goal is to build a unique clinical database that we hope can help optimise the development of existing and novel treatments while also allowing Emyria and our partner, Mind Medicine Australia to become the trusted and accredited clinical service of choice.”


Attached: Michael Winlo, Managing Director

ENDS 


Lexi O'Halloran

Account Director

 

Investor and Media Relations Consultants 

www.janemorganmanagement.com.au

P: + 61 404 577 076

E: lexi@janemorganmanagement.com.au

A: Level 1, 37 Bligh Street Sydney 


Media

Photos

949705